🇺🇸 FDA

Company profile · Sponsor

IRONWOOD

IRONWOOD PHARMACEUTICALS INC

IRWD · NYSE pharma BOSTON, MA, USA
Pipeline
24
Drugs
2
Patents
8

Quick answer

IRONWOOD (IRWD) is a pharma company. headquartered in BOSTON, MA, USA. listed on NYSE. NovaPharmaNews links 24 pipeline programs, 2 drugs, and 8 patents to this profile..

Company facts

Ticker IRWD
Exchange NYSE
Company type pharma
Headquarters BOSTON, MA, USA
SEC CIK 0001446847

Pipeline (24)

Search pipeline →

  1. IW-3718

    IRONWOOD

    Gastroesophageal Reflux Disease (GERD)

    phase 3 small molecule terminated

    2 trials

  2. Irritable Bowel Syndrome with Constipation (IBS-C) participants (LIN-MD-63 and LIN-MD-64 completers)

    IRONWOOD

    Irritable Bowel Syndrome With Constipation

    phase 3 small molecule completed

    1 trial

  3. Linaclotide

    IRONWOOD

    Chronic Idiopathic Constipation

    phase 3 small molecule completed

    1 trial

  4. Linaclotide

    IRONWOOD

    Functional Constipation

    phase 3 small molecule completed

    3 trials

  5. Linaclotide

    IRONWOOD

    Chronic Constipation

    phase 3 small molecule completed

    1 trial

  6. Linaclotide 290 micrograms

    IRONWOOD

    Irritable Bowel Syndrome Characterized by Constipation

    phase 3 small molecule completed

    1 trial

  7. Linaclotide 290 micrograms

    IRONWOOD

    Chronic Constipation

    phase 3 small molecule completed

    2 trials

  8. Linaclotide or Matching Placebo

    IRONWOOD

    Irritable Bowel Syndrome With Constipation

    phase 3 small molecule completed

    1 trial

  9. Matching Placebo

    IRONWOOD

    Chronic Constipation

    phase 3 small molecule completed

    1 trial

  10. Placebo

    IRONWOOD

    Irritable Bowel Syndrome With Constipation (IBS-C)

    phase 3 small molecule completed

    1 trial

  11. Placebo for Linaclotide

    IRONWOOD

    Functional Constipation (FC)

    phase 3 small molecule completed

    1 trial

  12. IW-3300 rectal foam

    IRONWOOD

    Interstitial Cystitis

    phase 2 small molecule terminated

    1 trial

  13. IW-3718

    IRONWOOD

    Gastroesophageal Reflux Disease

    phase 2 small molecule completed

    1 trial

  14. IW-3718

    IRONWOOD

    Gastroesophageal Reflux

    phase 2 small molecule completed

    1 trial

  15. IW-6118

    IRONWOOD

    Healthy

    phase 2 small molecule completed

    1 trial

  16. IW-9179

    IRONWOOD

    Dyspepsia

    phase 2 small molecule terminated

    1 trial

  17. IW-9179

    IRONWOOD

    Diabetic Gastroparesis

    phase 2 small molecule completed

    1 trial

  18. Linaclotide 145 micrograms

    IRONWOOD

    Opioid-Induced Constipation

    phase 2 small molecule completed

    1 trial

  19. Linaclotide Acetate

    IRONWOOD

    Irritable Bowel Syndrome With Constipation

    phase 2 small molecule completed

    1 trial

  20. Linaclotide Dose A

    IRONWOOD

    Irritable Bowel Syndrome With Constipation

    phase 2 small molecule terminated

    1 trial

  21. MD-0727

    IRONWOOD

    Hypercholesterolemia

    phase 2 small molecule completed

    1 trial

  22. MD-1100 Acetate

    IRONWOOD

    Constipation

    phase 2 small molecule completed

    1 trial

  23. MD-1100 Acetate

    IRONWOOD

    Irritable Bowel Syndrome

    phase 2 small molecule completed

    1 trial

  24. MD-7246

    IRONWOOD

    Irritable Bowel Syndrome With Diarrhea (IBS-D)

    phase 2 small molecule completed

    1 trial

Drugs (2)

Search drugs →

  1. allopurinol

    DUZALLO

    ORAL approved

    M04AA51

  2. lesinurad

    ZURAMPIC

    ORAL approved

    M04AB05

Patents (8)

Search patents →

  1. US 10702576

    Stable formulations of linaclotide

    Expires Mon Jul 02 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 10675325

    Stable formulations of linaclotide

    Expires Mon Jun 04 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 10618938

    Compositions for colon cleansing and the treatment of gastrointestinal disorders

    Expires Mon Apr 09 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 10266529

    Salts, co-crystals, and polymorphs of an anxiolytic compound

    Expires Mon Apr 18 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 10189809

    SGC stimulators

    Expires Mon Jan 24 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 10183021

    sGC stimulators

    Expires Mon Jan 17 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 10047095

    sGC stimulators

    Expires Mon Aug 09 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 9969742

    Imidazotriazinone compounds

    Expires Mon May 10 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is IRONWOOD?

IRONWOOD (IRWD) is a pharma company. headquartered in BOSTON, MA, USA. listed on NYSE. NovaPharmaNews links 24 pipeline programs, 2 drugs, and 8 patents to this profile..

What pipeline programs does IRONWOOD sponsor?

We track 24 ClinicalTrials.gov-linked programs for IRONWOOD, including IW-3718 and 23 more. Open each program for phase, modality, NCT IDs, and indication details.

Where does IRONWOOD company data come from?

Profiles combine SEC EDGAR (CIK/ticker), ClinicalTrials.gov sponsor links, FDA drug records, and USPTO patent metadata. See our data sources page. This profile is for professional reference, not investment advice.